$518 Million

Acceleron Pharma

Follow-on Offering

Bookrunner, July 2020

Acceleron Pharma

Acceleron Pharma Inc. is a biopharmaceutical company primarily focused on the discovery, development, and commercialization of therapeutics for the treatment of serious and rare diseases. The Company’s focus areas for research are hematology and pulmonary. REBLOZYL (luspatercept-aamt) – Acceleron’s first commercial product for the treatment of anemia in adult patients with beta-thalassemia, got approval from the FDA in November 2019. REBLOZYL is a first-in-class erythroid maturation agent that promotes RBC production for the treatment of blood-related disorders. The Company also received FDA approval of REBLOZYL in April 2020 for the treatment of very low-to intermediate-risk MDS with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPNRS-T). Additionally, under its hematology program, Acceleron has a pipeline of various clinical trials in partnership with BMS.